| 1 | English French Notes Complete/Exclude
|
|---|
| 2 | TYPE OF IMMUNOTHERAPY (BRM):
|
|---|
| 3 | TYPE OF FIRST RECURRENCE
|
|---|
| 4 | DATE OF FIRST RECURRENCE
|
|---|
| 5 | DISTANT SITE(S) OF FIRST RECURRENCE
|
|---|
| 6 | TABLE V - FIRST RECURRENCE
|
|---|
| 7 | 387TYPE OF FIRST RECURRENCE/BLADDER..
|
|---|
| 8 | DATE OF FIRST RECURRENCE..........:
|
|---|
| 9 | 70DATE OF FIRST RECURRENCE.........
|
|---|
| 10 | DISTANT SITE(S) OF RECURRENCE:
|
|---|
| 11 | 71.1 RECURRENCE SITE 1...........
|
|---|
| 12 | RECURRENCE SITE 2...........: None
|
|---|
| 13 | RECURRENCE SITE 3...........: None
|
|---|
| 14 | 71.2 RECURRENCE SITE 2...........
|
|---|
| 15 | 71.3 RECURRENCE SITE 3...........
|
|---|
| 16 | DATE OF LAST CONTACT OR DEATH
|
|---|
| 17 | VITAL STATUS
|
|---|
| 18 | CANCER STATUS
|
|---|
| 19 | REVIEWED BY CANCER COMMITTEE
|
|---|
| 20 | TABLE VI - STATUS AT LAST CONTACT
|
|---|
| 21 | DATE OF LAST CONTACT OR DEATH.......:
|
|---|
| 22 | 15VITAL STATUS........................
|
|---|
| 23 | CANCER STATUS.......................:
|
|---|
| 24 | 81COMPLETED BY........................
|
|---|
| 25 | 82REVIEWED BY CANCER COMMITTEE........
|
|---|
| 26 | ACCESSION/SEQUENCE NUMBER...........:
|
|---|
| 27 | CLASS OF CASE.......................:
|
|---|
| 28 | PATIENT REFERRED FOR TREATMENT......:
|
|---|
| 29 | ZIP CODE AT DIAGNOSIS...............:
|
|---|
| 30 | BIRTHDATE...........................:
|
|---|
| 31 | RACE................................:
|
|---|
| 32 | SPANISH ORIGIN......................:
|
|---|
| 33 | SEX.................................:
|
|---|
| 34 | PRIMARY PAYER AT DIAGNOSIS..........:
|
|---|
| 35 | LENGTH OF STAY......................:
|
|---|
| 36 | HEAD AND NECK:
|
|---|
| 37 | SMOKING HISTORY.....................:
|
|---|
| 38 | DURATION OF SMOKING HISTORY.........:
|
|---|
| 39 | DURATION OF SMOKE FREE HISTORY......:
|
|---|
| 40 | TABLE II - DIAGNOSTIC INFORMATION
|
|---|
| 41 | GROSS HEMATURIA...................:
|
|---|
| 42 | MICROSCOPIC HEMATURIA.............:
|
|---|
| 43 | URINARY FREQUENCY.................:
|
|---|
| 44 | BLADDER IRRITIBILITY..............:
|
|---|
| 45 | ONSET OF SYMPTOMS...................:
|
|---|
| 46 | DURATION OF SYMPTOMS:
|
|---|
| 47 | GROSS HEMTURIA....................:
|
|---|
| 48 | BIMANUAL EXAMINATION OF BLADDER...:
|
|---|
| 49 | CYSTOSCOPY WITH BIOPSY............:
|
|---|
| 50 | CYSTOSCOPY WITHOUT BIOPSY.........:
|
|---|
| 51 | FLOW CYTOMETRY....................:
|
|---|
| 52 | INTRAVENOUS PYELOGRAM.............:
|
|---|
| 53 | URINE CYTOLOGY....................:
|
|---|
| 54 | DATE OF INITIAL DIAGNOSIS...........:
|
|---|
| 55 | SPECIALTY MAKING DIAGNOSIS..........:
|
|---|
| 56 | PRIMARY SITE (ICD-O-2)..............:
|
|---|
| 57 | HISTOLOGY (ICD-O-2).................:
|
|---|
| 58 | GRADE...............................:
|
|---|
| 59 | TABLE III - EXTENT OF DISEASE AND AJCC STAGE
|
|---|
| 60 | ABDOMINAL ULTRASOUND:
|
|---|
| 61 | CT OTHER............:
|
|---|
| 62 | BONE IMAGING........:
|
|---|
| 63 | MRI PELVIS/ABDOMEN..:
|
|---|
| 64 | MRI OTHER...........:
|
|---|
| 65 | CT CHEST/LUNG.......:
|
|---|
| 66 | OTHER...............:
|
|---|
| 67 | CT ABDOMEN/PELVIS...:
|
|---|
| 68 | PRESENCE OF HYDRONEPHROSIS..........:
|
|---|
| 69 | TUMOR SIZE (mm).....................:
|
|---|
| 70 | PRESENCE OF MULTIPLE TUMORS.........:
|
|---|
| 71 | REGIONAL NODES EXAMINED.............:
|
|---|
| 72 | REGIONAL NODES POSITIVE.............:
|
|---|
| 73 | SITE(S) OF DISTANT METASTASIS:
|
|---|
| 74 | SITE OF DISTANT METASTASIS #1.....:
|
|---|
| 75 | SITE OF DISTANT METASTASIS #2.....:
|
|---|
| 76 | SITE OF DISTANT METASTASIS #3.....:
|
|---|
| 77 | AJCC STAGE........................:
|
|---|
| 78 | CLINICAL STAGE....................:
|
|---|
| 79 | PATHOLOGIC STAGE..................:
|
|---|
| 80 | Print Bladder PCE
|
|---|
| 81 | PCE Study of Cancers of the Urinary Bladder
|
|---|
| 82 | PROTOCOL ELIGIBILITY STATUS.........:
|
|---|
| 83 | PRIMARY PHYSICIAN.................:
|
|---|
| 84 | SECONDARY PHYSICIAN...............:
|
|---|
| 85 | TUMOR RESECTION DURING TURB.......:
|
|---|
| 86 | TYPE OF URINARY DIVERSION.........:
|
|---|
| 87 | PELVIC LYMPH NODE DISSECTION......:
|
|---|
| 88 | BLEEDING REQUIRING TRANSFUSION..:
|
|---|
| 89 | DEEP VENOUS THROMBOSIS..........:
|
|---|
| 90 | MYOCARDIAL INFARCTION/ARRHYTHMIA:
|
|---|
| 91 | PELVIC ABSCESS..................:
|
|---|
| 92 | PNEUMONIA REQUIRING ANTIBIOTICS.:
|
|---|
| 93 | POST-OPERATIVE DEATH (30 DAYS)..:
|
|---|
| 94 | PULMONARY EMBOLISM/THROMBOSIS...:
|
|---|
| 95 | DATE RADIATION THERAPY ENDED......:
|
|---|
| 96 | TOTAL RAD (cGy/rad) DOSE..........:
|
|---|
| 97 | REGIONAL TREATMENT MODALITY.......:
|
|---|
| 98 | URINARY INCONTINENCE............:
|
|---|
| 99 | RADIATION BOWEL INJURY..........:
|
|---|
| 100 | DATE CHEMOTHERAPY ENDED...........:
|
|---|
| 101 | ROUTE CHEMOTHERAPY ADMINISTERED...:
|
|---|
| 102 | IFOSFAMIDE......:
|
|---|
| 103 | METHOTREXATE....:
|
|---|
| 104 | TAXOL...........:
|
|---|
| 105 | THIOTEPA........:
|
|---|
| 106 | VINBLASTINE.....:
|
|---|
| 107 | GALLIUM NITRATE.:
|
|---|
| 108 | OTHER...........:
|
|---|
| 109 | INDICATION FOR ADMIN OF AGENTS...:
|
|---|
| 110 | REASON CHEMOTHERAPY STOPPED......:
|
|---|
| 111 | TYPE OF FIRST RECURRENCE............:
|
|---|
| 112 | DATE OF FIRST RECURRENCE............:
|
|---|
| 113 | DISTANT SITE OF FIRST RECURRENCE 1..:
|
|---|
| 114 | DISTANT SITE OF FIRST RECURRENCE 2..:
|
|---|
| 115 | DISTANT SITE OF FIRST RECURRENCE 3..:
|
|---|
| 116 | DATE OF LAST CONTACT OR DEATH......:
|
|---|
| 117 | VITAL STATUS.......................:
|
|---|
| 118 | CANCER STATUS......................:
|
|---|
| 119 | COMPLETED BY.......................:
|
|---|
| 120 | REVIEWED BY CANCER COMMITTEE.......:
|
|---|
| 121 | The Accession Year is not 1998.
|
|---|
| 122 | The Diagnostic Confirmation code is not 1 (Positive histology).
|
|---|
| 123 | The Class of Case code is not 1, 2 or 6.
|
|---|
| 124 | The Behavior Code is not 2 (In situ) or 3 (Malignant).
|
|---|
| 125 | Sex is neither 1 (Male) nor 2 (Female).
|
|---|
| 126 | Female patient has neither DCIS nor AJCC tumor size of T1mic or T1a.
|
|---|
| 127 | Select Table
|
|---|
| 128 | 1998 Patient Care Evaluation Study of Breast Cancer
|
|---|
| 129 | 1998 Patient Care Evaluation Study of Breast Cancer
|
|---|
| 130 | 1. INSTITUTION ID NUMBER
|
|---|
| 131 | 2. ACCESSION NUMBER
|
|---|
| 132 | 3. SEQUENCE NUMBER
|
|---|
| 133 | 4. POSTAL CODE AT DIAGNOSIS
|
|---|
| 134 | 5. DATE OF BIRTH
|
|---|
| 135 | 7. SPANISH ORIGIN
|
|---|
| 136 | 9. PRIMARY PAYER AT DIAGNOSIS
|
|---|
| 137 | 10. FAMILY HISTORY OF BREAST CANCER
|
|---|
| 138 | 11. (F) PERSONAL HISTORY OF BREAST CANCER
|
|---|
| 139 | 12. SYNCHRONOUS BREAST CANCER
|
|---|
| 140 | 13. PERSONAL HISTORY OF OTHER CANCER
|
|---|
| 141 | 14. (F) HORMONE REPLACEMENT THERAPY
|
|---|
| 142 | 15. (F) HOW MANY YEARS OF HORMONE REPLACEMENT THERAPY
|
|---|
| 143 | 1. INSTITUTION ID NUMBER
|
|---|
| 144 | 2. ACCESSION NUMBER
|
|---|
| 145 | 3. SEQUENCE NUMBER
|
|---|
| 146 | 4. POSTAL CODE AT DIAGNOSIS
|
|---|
| 147 | 5. DATE OF BIRTH
|
|---|
| 148 | 7. SPANISH ORIGIN
|
|---|
| 149 | 9. PRIMARY PAYER AT DIAGNOSIS
|
|---|
| 150 | 1. INSTITUTION ID NUMBER..........: H6
|
|---|
| 151 | TABLE I - GENERAL INFORMATION
|
|---|
| 152 | 2. ACCESSION NUMBER...............:
|
|---|
| 153 | 3. SEQUENCE NUMBER................:
|
|---|
| 154 | 9 4. POSTAL CODE AT DIAGNOSIS.......
|
|---|
| 155 | 5. DATE OF BIRTH..................:
|
|---|
| 156 | 9 7. SPANISH ORIGIN.................
|
|---|
| 157 | 18 9. PRIMARY PAYER AT DIAGNOSIS.....
|
|---|
| 158 | 10. FAMILY HISTORY OF BREAST CANCER:
|
|---|
| 159 | 901 MATERNAL AUNT..................
|
|---|
| 160 | 902 MATERNAL GRANDMOTHER...........
|
|---|
| 161 | 904 ONE SISTER ONLY................
|
|---|
| 162 | 905 MORE THAN ONE SISTER...........
|
|---|
| 163 | 908 POSITIVE FAMILY HISTORY, NOS...
|
|---|
| 164 | 11. (F) PERSONAL HISTORY OF BREAST
|
|---|
| 165 | CANCER.........................: (Data Item for Females Only)
|
|---|
| 166 | 909 11. (F) PERSONAL HISTORY OF BREAST CANCER.........................
|
|---|
| 167 | 910 12. SYNCHRONOUS BREAST CANCER......
|
|---|
| 168 | 13. PERSONAL HISTORY OF OTHER CANCER:
|
|---|
| 169 | OVARY (F)......................: (Data Item for Females Only)
|
|---|
| 170 | UTERUS (F).....................: (Data Item for Females Only)
|
|---|
| 171 | PROSTATE (M)...................: (Data Item for Males Only)
|
|---|
| 172 | 14. (F) HORMONE REPLACEMENT THERAPY: (Data Item for Females Only)
|
|---|
| 173 | 916 14. (F) HORMONE REPLACEMENT THERAPY
|
|---|
| 174 | 15. (F) HOW MANY YEARS OF HORMONE
|
|---|
| 175 | REPLACEMENT THERAPY............: NA
|
|---|
| 176 | REPLACEMENT THERAPY............: Unknown
|
|---|
| 177 | REPLACEMENT THERAPY............: (Data Item for Females Only)
|
|---|
| 178 | 917 15. (F) HOW MANY YEARS OF HORMONE REPLACEMENT THERAPY............
|
|---|
| 179 | GO TO ITEM NUMBER:
|
|---|
| 180 | CHOOSE FROM:
|
|---|
| 181 | 16. CLASS OF CASE
|
|---|
| 182 | 17. DIAGNOSTIC EVALUATION
|
|---|
| 183 | 18. (F) TYPE OF MAMMOGRAM
|
|---|
| 184 | 19. (F) PRESENTATION OF MOST DEFINITIVE MAMMOGRAM
|
|---|
| 185 | 20. DATE OF INITIAL DIAGNOSIS
|
|---|
| 186 | 21. DATE OF PATHOLOGIC DIAGNOSIS
|
|---|
| 187 | 22. PRIMARY SITE (ICD-O-2)
|
|---|
| 188 | 24. BEHAVIOR CODE(ICD-O-2)
|
|---|
| 189 | 25. IF INVASIVE DUCTAL CARCINOMA REPORTED, IS DCIS ALSO PRESENT
|
|---|
| 190 | 27. ARCHITECTURE PATTERN IF DCIS IS PRESENT
|
|---|
| 191 | 28. NUCLEAR GRADE IF DCIS IS PRESENT
|
|---|
| 192 | 29. DIAGNOSTIC CONFIRMATION
|
|---|
| 193 | 30. (M) LEVEL OF INVOLVEMENT
|
|---|
| 194 | 31. BIOPSY PROCEDURE
|
|---|
| 195 | 33. PALPABILITY OF PRIMARY
|
|---|
| 196 | 34. FIRST DETECTED BY
|
|---|
| 197 | 24. BEHAVIOR CODE (ICD-O-2)
|
|---|
| 198 | TABLE II - INITIAL DIAGNOSIS
|
|---|
| 199 | 16. CLASS OF CASE.................:
|
|---|
| 200 | 17. DIAGNOSTIC EVALUATION:
|
|---|
| 201 | MAMMOGRAM (M).................: (Data Item for Males Only)
|
|---|
| 202 | 18. (F) TYPE OF MAMMOGRAM:
|
|---|
| 203 | A. MAMMOGRAM GIVEN, TYPE UNKNOWN.: (Data Item for Females Only)
|
|---|
| 204 | B. SCREENING MAMMOGRAM...........: (Data Item for Females Only)
|
|---|
| 205 | C. DIAGNOSTIC MAMMOGRAM..........: (Data Item for Females Only)
|
|---|
| 206 | D. MAGNIFICATION MAMMOGRAM.......: (Data Item for Females Only)
|
|---|
| 207 | 918 A. MAMMOGRAM GIVEN, TYPE UNKNOWN.
|
|---|
| 208 | 920 B. SCREENING MAMMOGRAM...........
|
|---|
| 209 | 922 C. DIAGNOSTIC MAMMOGRAM..........
|
|---|
| 210 | 924 D. MAGNIFICATION MAMMOGRAM.......
|
|---|
| 211 | 19. (F) PRESENTATION OF MOST
|
|---|
| 212 | DEFINITIVE MAMMOGRAM..........: (Data Item for Females Only)
|
|---|
| 213 | 928 19. (F) PRESENTATION OF MOST DEFINITIVE MAMMOGRAM..........
|
|---|
| 214 | 20. DATE OF INITIAL DIAGNOSIS.....:
|
|---|
| 215 | 929 21. DATE OF PATHOLOGIC DIAGNOSIS..
|
|---|
| 216 | 22. PRIMARY SITE (ICD-O-2)........:
|
|---|
| 217 | 24. BEHAVIOR CODE (ICD-O-2).......:
|
|---|
| 218 | 25. IF INVASIVE DUCTAL CARCINOMA
|
|---|
| 219 | REPORTED, IS DCIS ALSO PRESENT: NA, reported tumor not invasive DC
|
|---|
| 220 | 930 25. IF INVASIVE DUCTAL CARCINOMA REPORTED, IS DCIS ALSO PRESENT
|
|---|
| 221 | 931 27. ARCHITECTURE PATTERN IF DCIS IS PRESENT....................
|
|---|
| 222 | 932 28. NUCLEAR GRADE IF DCIS IS PRESENT.......................
|
|---|
| 223 | 26. DIAGNOSTIC CONFIRMATION.......:
|
|---|
| 224 | 30. (M) LEVEL OF INVOLVEMENT:
|
|---|
| 225 | SKIN..........................: (Data Item for Males Only)
|
|---|
| 226 | CHEST WALL....................: (Data Item for Males Only)
|
|---|
| 227 | PECTORAL MUSCLES..............: (Data Item for Males Only)
|
|---|
| 228 | DERMAL/LYMPHATIC..............: (Data Item for Males Only)
|
|---|
| 229 | 934 CHEST WALL....................
|
|---|
| 230 | 935 PECTORAL MUSCLES..............
|
|---|
| 231 | DIAGNOSTIC AND STAGING PROCEDURES
|
|---|
| 232 | 141 31. BIOSPY PROCEDURE..............
|
|---|
| 233 | 32. GUIDANCE......................: Not guided, no biopsy
|
|---|
| 234 | 32. GUIDANCE......................: Unknown/death cert only
|
|---|
| 235 | 143 33. PALPABILITY OF PRIMARY........
|
|---|
| 236 | 144 34. FIRST DETECTED BY.............
|
|---|
| 237 | 35. (M) DNA INDEX/PLOIDY
|
|---|
| 238 | 36. ESTROGEN RECEPTOR PROTEIN
|
|---|
| 239 | 37. PROGESTERONE RECEPTOR PROTEIN
|
|---|
| 240 | 38. (M) ANDROGEN RECEPTOR PROTEIN
|
|---|
| 241 | 39. TYPE OF TEST
|
|---|
| 242 | TABLE III - TUMOR MARKERS AND PROGNOSTIC TESTS
|
|---|
| 243 | 35. (M) DNA INDEX/PLOIDY.........: (Data Item for Males Only)
|
|---|
| 244 | 937 35. (M) DNA INDEX PLOIDY.........
|
|---|
| 245 | 36. ESTROGEN RECEPTOR PROTEIN....:
|
|---|
| 246 | 37. PROGESTERONE RECEPTOR PROTEIN:
|
|---|
| 247 | 38. (M) ANDROGEN RECEPTOR PROTEIN: (Data Item for Males Only)
|
|---|
| 248 | 940 38. (M) ANDROGEN RECEPTOR PROTEIN
|
|---|
| 249 | 39. TYPE OF TEST.................: Neither ERA nor PRA was done
|
|---|
| 250 | 39. TYPE OF TEST.................: Unknown if ERA/PRA was done
|
|---|
| 251 | 941 39. TYPE OF TEST.................
|
|---|
| 252 | 40. SIZE OF TUMOR (mm)
|
|---|
| 253 | 41. SIZE OF DCIS TUMOR (mm)
|
|---|
| 254 | 42. REGIONAL NODES EXAMINED
|
|---|
| 255 | 43. REGIONAL NODES POSITIVE
|
|---|
| 256 | 44. SENTINEL NODE BIOSPY
|
|---|
| 257 | 45. NUMBER OF SENTINEL NODES EXAMINED
|
|---|
| 258 | 46. NUMBER OF SENTINEL NODES POSITIVE
|
|---|
| 259 | 47. SENTINEL NODE DETECTED BY
|
|---|
| 260 | 48. AJCC CLINICAL STAGE (cTNM)
|
|---|
| 261 | 49. AJCC PATHOLOGIC STAGE (pTNM)
|
|---|
| 262 | 50. STAGED BY
|
|---|
| 263 | TABLE IV - EXTENT OF DISEASE AND AJCC STAGE
|
|---|
| 264 | 29 40. SIZE OF TUMOR (mm).......
|
|---|
| 265 | 41. SIZE OF DCIS TUMOR (mm)..: NA, reported tumor not invasive DC
|
|---|
| 266 | 942 41. SIZE OF DCIS TUMOR (mm)..
|
|---|
| 267 | 33 42. REGIONAL NODES EXAMINED..
|
|---|
| 268 | 32 43. REGIONAL NODES POSITIVE..
|
|---|
| 269 | SENTINEL NODES
|
|---|
| 270 | 943 44. SENTINEL NODE BIOPSY.....
|
|---|
| 271 | 45. NUMBER OF SENTINEL NODES
|
|---|
| 272 | 46. NUMBER OF SENTINEL NODES
|
|---|
| 273 | POSITIVE.................: None examined
|
|---|
| 274 | 47. SENTINEL NODE DETECTED BY: NA, not done
|
|---|
| 275 | EXAMINED.................: Unknown if examined
|
|---|
| 276 | POSITIVE.................: Unknown if positive
|
|---|
| 277 | 47. SENTINEL NODE DETECTED BY: Method unknown
|
|---|
| 278 | 944 45. NUMBER OF SENTINEL NODES EXAMINED.................
|
|---|
| 279 | 945 46. NUMBER OF SENTINEL NODES POSITIVE.................
|
|---|
| 280 | 946 47. SENTINEL NODE DETECTED BY
|
|---|
| 281 | 48. AJCC CLINICAL STAGE (cTNM):
|
|---|
| 282 | 49. AJCC PATHOLOGIC STAGE (pTNM):
|
|---|
| 283 | 50. STAGED BY:
|
|---|
| 284 | 19 CLINICAL STAGE...........
|
|---|
| 285 | 89 PATHOLOGIC STAGE.........
|
|---|
| 286 | NON CANCER-DIRECTED SURGERY
|
|---|
| 287 | CANCER-DIRECTED SURGERY
|
|---|
| 288 | HORMONE THERAPY
|
|---|
| 289 | TABLE V - FIRST COURSE OF TREATMENT
|
|---|
| 290 | 51. DATE OF FIRST COURSE TREATMENT:
|
|---|
| 291 | NON CANCER-DIRECTED SURGERY
|
|---|
| 292 | 52. DATE OF NON CANCER-DIRECTED
|
|---|
| 293 | 53. NON CANCER-DIRECTED SURGERY...:
|
|---|
| 294 | CANCER-DIRECTED SURGERY
|
|---|
| 295 | 54. DATE (FIRST) OF CANCER-
|
|---|
| 296 | DIRECTED SURGERY..............:
|
|---|
| 297 | 55. SURGICAL APPROACH.............:
|
|---|
| 298 | 56. SURGERY OF PRIMARY SITE.......:
|
|---|
| 299 | 57. SPECIMEN RADIOGRAPH...........: NA
|
|---|
| 300 | 57. SPECIMEN RADIOGRAPH...........: Unknown
|
|---|
| 301 | 947 57. SPECIMEN RADIOGRAPH...........
|
|---|
| 302 | 58. SURGICAL MARGINS..............:
|
|---|
| 303 | #################### #################### ####################
|
|---|
| 304 | #################### #################### ####################
|
|---|
| 305 | #################### #################### ####################
|
|---|
| 306 | #################### #################### ####################
|
|---|
| 307 | #################### #################### ####################
|
|---|
